Merck EBITDA 2012-2025 | MRK
Merck annual and quarterly EBITDA history from 2012 to 2025. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Merck EBITDA for the quarter ending December 31, 2025 was $7.708B, a 49.09% increase year-over-year.
- Merck EBITDA for the twelve months ending December 31, 2025 was $26.961B, a 46.32% increase year-over-year.
- Merck 2024 annual EBITDA was $24.72B, a 262.14% increase from 2023.
- Merck 2023 annual EBITDA was $6.826B, a 69.24% decline from 2022.
- Merck 2022 annual EBITDA was $22.191B, a 35.2% increase from 2021.
|
Merck Annual EBITDA (Millions of US $) |
|
|---|---|
| 2024 | $24,720 |
| 2023 | $6,826 |
| 2022 | $22,191 |
| 2021 | $16,413 |
| 2020 | $9,034 |
| 2019 | $11,236 |
| 2018 | $13,450 |
| 2017 | $11,473 |
| 2016 | $10,970 |
| 2015 | $13,922 |
| 2014 | $13,374 |
| 2013 | $14,653 |
| 2012 | $16,855 |
| 2011 | $16,403 |
|
Merck Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2025-09-30 | $7,708 |
| 2025-06-30 | $6,671 |
| 2025-03-31 | $7,036 |
| 2024-12-31 | $5,546 |
| 2024-09-30 | $5,170 |
| 2024-06-30 | $7,260 |
| 2024-03-31 | $6,744 |
| 2023-12-31 | $-748 |
| 2023-09-30 | $6,886 |
| 2023-06-30 | $-4,109 |
| 2023-03-31 | $4,797 |
| 2022-12-31 | $4,379 |
| 2022-09-30 | $5,065 |
| 2022-06-30 | $6,005 |
| 2022-03-31 | $6,742 |
| 2021-12-31 | $4,586 |
| 2021-09-30 | $5,682 |
| 2021-06-30 | $2,424 |
| 2021-03-31 | $3,721 |
| 2020-12-31 | $-2,493 |
| 2020-09-30 | $3,314 |
| 2020-06-30 | $3,411 |
| 2020-03-31 | $4,802 |
| 2019-12-31 | $-960 |
| 2019-09-30 | $3,459 |
| 2019-06-30 | $4,431 |
| 2019-03-31 | $4,306 |
| 2018-12-31 | $3,850 |
| 2018-09-30 | $3,758 |
| 2018-06-30 | $3,556 |
| 2018-03-31 | $2,286 |
| 2017-12-31 | $3,203 |
| 2017-09-30 | $1,300 |
| 2017-06-30 | $3,694 |
| 2017-03-31 | $3,276 |
| 2016-12-31 | $194 |
| 2016-09-30 | $4,245 |
| 2016-06-30 | $3,207 |
| 2016-03-31 | $3,324 |
| 2015-12-31 | $3,512 |
| 2015-09-30 | $3,910 |
| 2015-06-30 | $3,345 |
| 2015-03-31 | $3,155 |
| 2014-12-31 | $3,099 |
| 2014-09-30 | $3,311 |
| 2014-06-30 | $3,157 |
| 2014-03-31 | $3,807 |
| 2013-12-31 | $3,851 |
| 2013-09-30 | $4,170 |
| 2013-06-30 | $3,140 |
| 2013-03-31 | $3,492 |
| 2012-12-31 | $3,625 |
| 2012-09-30 | $4,093 |
| 2012-06-30 | $4,589 |
| 2012-03-31 | $4,548 |
| 2011-12-31 | $3,856 |
| 2011-09-30 | $4,279 |
| 2011-06-30 | $4,238 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $299.893B | $65.011B |
| Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |